Published in J Clin Invest on January 26, 2006
Inflammation in neurodegenerative diseases. Immunology (2010) 3.22
Toll-like receptor 2 signaling in CD4(+) T lymphocytes promotes T helper 17 responses and regulates the pathogenesis of autoimmune disease. Immunity (2010) 2.90
Stimulation of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model of arthritis. J Clin Invest (2008) 2.82
The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. J Clin Invest (2008) 2.66
TREM2-transduced myeloid precursors mediate nervous tissue debris clearance and facilitate recovery in an animal model of multiple sclerosis. PLoS Med (2007) 2.62
Toll-like receptors in neurodegeneration. Brain Res Rev (2008) 2.15
Toll-like receptor signaling in neural plasticity and disease. Trends Neurosci (2011) 2.01
Cytosolic RIG-I-like helicases act as negative regulators of sterile inflammation in the CNS. Nat Neurosci (2011) 1.96
TLR-dependent T cell activation in autoimmunity. Nat Rev Immunol (2011) 1.88
Signaling via the RIP2 adaptor protein in central nervous system-infiltrating dendritic cells promotes inflammation and autoimmunity. Immunity (2011) 1.78
Toll-like receptors in health and disease in the brain: mechanisms and therapeutic potential. Clin Sci (Lond) (2011) 1.73
Emerging role of Toll-like receptors in the control of pain and itch. Neurosci Bull (2012) 1.60
Methylation patterns of cell-free plasma DNA in relapsing-remitting multiple sclerosis. J Neurol Sci (2010) 1.59
Toll-like receptor signaling pathways--therapeutic opportunities. Mediators Inflamm (2010) 1.58
Unc93B1 biases Toll-like receptor responses to nucleic acid in dendritic cells toward DNA- but against RNA-sensing. J Exp Med (2009) 1.53
Role of the innate immune system in the pathogenesis of multiple sclerosis. J Neuroimmunol (2010) 1.42
Endogenous toll-like receptor ligands and their biological significance. J Cell Mol Med (2010) 1.41
Initiation and progression of axonopathy in experimental autoimmune encephalomyelitis. J Neurosci (2009) 1.41
Glial toll-like receptor signaling in central nervous system infection and autoimmunity. Brain Behav Immun (2007) 1.40
IkappaB kinase 2 determines oligodendrocyte loss by non-cell-autonomous activation of NF-kappaB in the central nervous system. Brain (2011) 1.37
Unexpected protective role for Toll-like receptor 3 in the arterial wall. Proc Natl Acad Sci U S A (2011) 1.31
Toll-like receptor (TLR) and inflammasome actions in the central nervous system. Trends Immunol (2012) 1.30
Peroxisome proliferator-activated receptor-alpha agonist fenofibrate regulates IL-12 family cytokine expression in the CNS: relevance to multiple sclerosis. J Neurochem (2007) 1.19
Functional characterization of aquaporin-4 specific T cells: towards a model for neuromyelitis optica. PLoS One (2011) 1.13
Prevention of autoimmune disease by induction of tolerance to Toll-like receptor 7. Proc Natl Acad Sci U S A (2009) 1.10
Peli1 promotes microglia-mediated CNS inflammation by regulating Traf3 degradation. Nat Med (2013) 1.08
Role of microglia in neuronal degeneration and regeneration. Semin Immunopathol (2009) 1.06
TLR8: an innate immune receptor in brain, neurons and axons. Cell Cycle (2007) 1.05
Acute brain injury triggers MyD88-dependent, TLR2/4-independent inflammatory responses. Am J Pathol (2007) 1.03
Models of autoimmune demyelination in the central nervous system: on the way to translational medicine. Exp Transl Stroke Med (2009) 1.03
Regulation of the severity of neuroinflammation and demyelination by TLR-ASK1-p38 pathway. EMBO Mol Med (2010) 1.00
The role of TLR2, TRL3, TRL4, and TRL9 signaling in the pathogenesis of autoimmune disease in a retinal autoimmunity model. Invest Ophthalmol Vis Sci (2010) 1.00
Phagocytes containing a disease-promoting Toll-like receptor/Nod ligand are present in the brain during demyelinating disease in primates. Am J Pathol (2006) 1.00
Suppression of immune responses by nonimmunogenic oligodeoxynucleotides with high affinity for high-mobility group box proteins (HMGBs). Proc Natl Acad Sci U S A (2011) 0.98
Toll-like receptors are key players in neurodegeneration. Int Immunopharmacol (2011) 0.95
Role of toll-like receptors in multiple sclerosis. Am J Clin Exp Immunol (2013) 0.94
Modeling multiple sclerosis in laboratory animals. Semin Immunopathol (2009) 0.94
Regulatory role of TLR ligands on the activation of autoreactive T cells by retinal astrocytes. Invest Ophthalmol Vis Sci (2009) 0.93
Identification of the synthetic cannabinoid R(+)WIN55,212-2 as a novel regulator of IFN regulatory factor 3 activation and IFN-beta expression: relevance to therapeutic effects in models of multiple sclerosis. J Biol Chem (2011) 0.92
Streptococcus pneumoniae Infection aggravates experimental autoimmune encephalomyelitis via Toll-like receptor 2. Infect Immun (2006) 0.91
Toll-like receptors in multiple sclerosis. Curr Top Microbiol Immunol (2009) 0.90
CCL22 regulates experimental autoimmune encephalomyelitis by controlling inflammatory macrophage accumulation and effector function. J Leukoc Biol (2010) 0.90
Design, synthesis and biological evaluation of novel antagonist compounds of Toll-like receptors 7, 8 and 9. Nucleic Acids Res (2013) 0.89
15-deoxy-Delta(12,14)-prostaglandin J(2) and curcumin modulate the expression of toll-like receptors 4 and 9 in autoimmune T lymphocyte. J Clin Immunol (2008) 0.89
1,25-Dihydroxyvitamin D3 suppresses TLR8 expression and TLR8-mediated inflammatory responses in monocytes in vitro and experimental autoimmune encephalomyelitis in vivo. PLoS One (2013) 0.88
The potential of mesenchymal stromal cells as a novel cellular therapy for multiple sclerosis. Immunotherapy (2012) 0.88
Toll-like receptor 4 deficiency accelerates the development of insulin-deficient diabetes in non-obese diabetic mice. PLoS One (2013) 0.87
Human herpesvirus 6A infection in CD46 transgenic mice: viral persistence in the brain and increased production of proinflammatory chemokines via Toll-like receptor 9. J Virol (2014) 0.86
Inactivation of JNK1 enhances innate IL-10 production and dampens autoimmune inflammation in the brain. Proc Natl Acad Sci U S A (2006) 0.86
Interferon regulatory factor-7 modulates experimental autoimmune encephalomyelitis in mice. J Neuroinflammation (2011) 0.86
The Role of Dendritic Cell Subsets and Innate Immunity in the Pathogenesis of Type 1 Diabetes and Other Autoimmune Diseases. Front Immunol (2015) 0.85
Constitutive activity of NF-kappa B in myeloid cells drives pathogenicity of monocytes and macrophages during autoimmune neuroinflammation. J Neuroinflammation (2012) 0.85
Deletion of astroglial CXCL10 delays clinical onset but does not affect progressive axon loss in a murine autoimmune multiple sclerosis model. J Neuroinflammation (2014) 0.83
Glatiramer acetate treatment negatively regulates type I interferon signaling. Neurol Neuroimmunol Neuroinflamm (2015) 0.83
VBP15, a novel anti-inflammatory, is effective at reducing the severity of murine experimental autoimmune encephalomyelitis. Cell Mol Neurobiol (2014) 0.83
Epstein-Barr virus latent membrane protein 2A exacerbates experimental autoimmune encephalomyelitis and enhances antigen presentation function. Sci Rep (2012) 0.81
Toll-Like Receptors in the Pathogenesis of Autoimmune Diseases. Adv Pharm Bull (2015) 0.81
IRAK-M deficiency promotes the development of type 1 diabetes in NOD mice. Diabetes (2014) 0.80
Recent developments in animal models for human herpesvirus 6A and 6B. Curr Opin Virol (2014) 0.80
Initial immunopathogenesis of multiple sclerosis: innate immune response. Clin Dev Immunol (2013) 0.80
Cannabinoid modulation of neuroinflammatory disorders. Curr Neuropharmacol (2012) 0.80
Targeting innate receptors with MIS416 reshapes Th responses and suppresses CNS disease in a mouse model of multiple sclerosis. PLoS One (2014) 0.80
Tolerance induction in experimental autoimmune encephalomyelitis using non-myeloablative hematopoietic gene therapy with autoantigen. Mol Ther (2009) 0.79
Comparison of a classical Th1 bacteria versus a Th17 bacteria as adjuvant in the induction of experimental autoimmune encephalomyelitis. J Neuroimmunol (2011) 0.79
Does helminth activation of toll-like receptors modulate immune response in multiple sclerosis patients? Front Cell Infect Microbiol (2012) 0.79
Peli1 sets the CNS on fire. Nat Med (2013) 0.79
Treatment of autoimmune inflammation by a TLR7 ligand regulating the innate immune system. PLoS One (2012) 0.78
IL-10 Modulates Th17 Pathogenicity during Autoimmune Diseases. J Clin Cell Immunol (2016) 0.78
Toll-like receptors 4 and 9 are responsible for the maintenance of the inflammatory reaction in canine steroid-responsive meningitis-arteritis, a large animal model for neutrophilic meningitis. J Neuroinflammation (2012) 0.77
Delayed onset of experimental autoimmune encephalomyelitis in Olig1 deficient mice. PLoS One (2010) 0.77
Humanized TLR7/8 expression drives proliferative multisystemic histiocytosis in C57BL/6 mice. PLoS One (2014) 0.77
Endogenous Toll-Like Receptor 9 Regulates AKI by Promoting Regulatory T Cell Recruitment. J Am Soc Nephrol (2015) 0.77
Engagement of Toll-like receptor 2 enhances interleukin (IL)-17(+) autoreactive T cell responses via p38 mitogen-activated protein kinase signalling in dendritic cells. Clin Exp Immunol (2014) 0.76
Polyplexes assembled from self-peptides and regulatory nucleic acids blunt toll-like receptor signaling to combat autoimmunity. Biomaterials (2016) 0.75
Autophagy and Autophagy-Related Proteins in CNS Autoimmunity. Front Immunol (2017) 0.75
Neurogenesis-Promoting Natural Product α-Asarone Modulates Morphological Dynamics of Activated Microglia. Front Cell Neurosci (2016) 0.75
Toll-Like Receptor 2 Mediates In Vivo Pro- and Anti-inflammatory Effects of Mycobacterium Tuberculosis and Modulates Autoimmune Encephalomyelitis. Front Immunol (2016) 0.75
Impact of Exercise on Innate Immunity in Multiple Sclerosis Progression and Symptomatology. Front Physiol (2016) 0.75
CpG Type A Induction of an Early Protective Environment in Experimental Multiple Sclerosis. Mediators Inflamm (2017) 0.75
Effect of glucocorticoid on cytokines TLR9 and TLR7 in peripheral blood for patients with uveitis. Exp Ther Med (2016) 0.75
Liver X receptor-dependent inhibition of microglial nitric oxide synthase 2. J Neuroinflammation (2015) 0.75
Alteration of T cell cytokine production in PLPp-139-151-induced EAE in SJL mice by an immunostimulatory CpG oligonucleotide. J Neuroinflammation (2011) 0.75
Transcriptome Analysis of Peripheral Blood in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients Identifies TNFR1 and TLR Pathways in the IVIg Response. Medicine (Baltimore) (2016) 0.75
Inhibition of Myeloid Differentiation Factor 88 Reduces Human and Mouse T-Cell Interleukin-17 and IFNγ Production and Ameliorates Experimental Autoimmune Encephalomyelitis Induced in Mice. Front Immunol (2017) 0.75
DNA repair and systemic lupus erythematosus. DNA Repair (Amst) (2017) 0.75
TLR-Induced Murine Dendritic Cell (DC) Activation Requires DC-Intrinsic Complement. J Immunol (2017) 0.75
TLR7 Signaling Regulates Th17 Cells and Autoimmunity: Novel Potential for Autoimmune Therapy. J Immunol (2017) 0.75
Dendritic cells and the control of immunity. Nature (1998) 56.54
A Toll-like receptor recognizes bacterial DNA. Nature (2000) 26.34
Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity (1998) 18.12
The dorsoventral regulatory gene cassette spätzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell (1996) 17.42
Tolerance, danger, and the extended family. Annu Rev Immunol (1994) 14.94
The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature (2001) 14.24
Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science (2003) 14.04
Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol (2002) 13.10
Toll-like receptors in innate immunity. Int Immunol (2005) 12.24
Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity (1999) 11.64
Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature (2002) 11.05
MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol Cell (1998) 8.73
Inferences, questions and possibilities in Toll-like receptor signalling. Nature (2004) 7.57
Toll-like receptors control activation of adaptive immune responses. Nat Immunol (2001) 7.54
Multiple sclerosis. Lancet (2002) 7.11
IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science (1997) 6.30
Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. J Immunol (2004) 5.15
Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway. Proc Natl Acad Sci U S A (2003) 5.11
Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat Med (2005) 4.67
Experimental autoimmune encephalomyelitis repressed by microglial paralysis. Nat Med (2005) 4.42
Leptospiral lipopolysaccharide activates cells through a TLR2-dependent mechanism. Nat Immunol (2001) 4.13
Broad expression of Toll-like receptors in the human central nervous system. J Neuropathol Exp Neurol (2002) 3.53
Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell (1996) 3.48
Targeting gene-modified hematopoietic cells to the central nervous system: use of green fluorescent protein uncovers microglial engraftment. Nat Med (2001) 3.32
Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain (2002) 2.89
Toll-dependent control mechanisms of CD4 T cell activation. Immunity (2004) 2.88
Bone marrow-derived elements in the central nervous system: an immunohistochemical and ultrastructural survey of rat chimeras. J Neuropathol Exp Neurol (1992) 2.19
Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6. J Exp Med (2000) 2.16
Cellular responses to bacterial cell wall components are mediated through MyD88-dependent signaling cascades. Int Immunol (2000) 2.05
Endosomal translocation of vertebrate DNA activates dendritic cells via TLR9-dependent and -independent pathways. J Immunol (2005) 2.02
Selection for T-cell receptor V beta-D beta-J beta gene rearrangements with specificity for a myelin basic protein peptide in brain lesions of multiple sclerosis. Nature (1993) 2.01
Toll-like receptor pathways in the immune responses to mycobacteria. Microbes Infect (2004) 1.94
Toll-like receptor 2 participates in mediation of immune response in experimental pneumococcal meningitis. J Immunol (2003) 1.93
The clinical course of experimental autoimmune encephalomyelitis and inflammation is controlled by the expression of CD40 within the central nervous system. J Exp Med (2001) 1.86
TLR4 contributes to disease-inducing mechanisms resulting in central nervous system autoimmune disease. J Immunol (2004) 1.70
Positioning of follicular dendritic cells within the spleen controls prion neuroinvasion. Nature (2003) 1.51
IL-23 produced by CNS-resident cells controls T cell encephalitogenicity during the effector phase of experimental autoimmune encephalomyelitis. J Clin Invest (2003) 1.50
CpG oligonucleotides are potent adjuvants for the activation of autoreactive encephalitogenic T cells in vivo. J Immunol (2000) 1.30
Human CD34+ cells differentiate into microglia and express recombinant therapeutic protein. Proc Natl Acad Sci U S A (2004) 1.28
T-cell apoptosis in inflammatory brain lesions: destruction of T cells does not depend on antigen recognition. Am J Pathol (1998) 1.19
Genetic models for CNS inflammation. Nat Med (2001) 1.10
Prion pathogenesis in the absence of Toll-like receptor signalling. EMBO Rep (2003) 1.07
Prognosis of multiple sclerosis: environmental factors. Neurol Sci (2000) 0.81
RORγt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat Immunol (2011) 6.96
Microglia in the adult brain arise from Ly-6ChiCCR2+ monocytes only under defined host conditions. Nat Neurosci (2007) 6.23
Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med (2007) 6.19
Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity (2012) 6.18
Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain (2005) 5.29
Massively parallel single-cell RNA-seq for marker-free decomposition of tissues into cell types. Science (2014) 4.91
Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat Med (2005) 4.67
Experimental autoimmune encephalomyelitis repressed by microglial paralysis. Nat Med (2005) 4.42
The immunopathology of multiple sclerosis: an overview. Brain Pathol (2007) 4.23
HSP70 as endogenous stimulus of the Toll/interleukin-1 receptor signal pathway. J Biol Chem (2002) 4.03
Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med (2011) 4.02
Brummer lipase is an evolutionary conserved fat storage regulator in Drosophila. Cell Metab (2005) 3.93
Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity (2008) 3.67
IL-17A and IL-17F do not contribute vitally to autoimmune neuro-inflammation in mice. J Clin Invest (2008) 3.64
Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline. Nat Med (2012) 3.49
Renal-associated TLR2 mediates ischemia/reperfusion injury in the kidney. J Clin Invest (2005) 3.48
Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J Exp Med (2005) 3.42
Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain (2011) 3.38
RORgamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. Gastroenterology (2008) 3.13
Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain. Brain (2009) 3.04
A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis. Nat Med (2011) 3.00
Toll-like receptor 2 is required for innate, but not acquired, host defense to Borrelia burgdorferi. J Immunol (2002) 2.98
Hemagglutinin protein of wild-type measles virus activates toll-like receptor 2 signaling. J Virol (2002) 2.86
Activated leukocyte cell adhesion molecule promotes leukocyte trafficking into the central nervous system. Nat Immunol (2007) 2.85
IL-9 as a mediator of Th17-driven inflammatory disease. J Exp Med (2009) 2.78
Helicobacter pylori infection prevents allergic asthma in mouse models through the induction of regulatory T cells. J Clin Invest (2011) 2.77
Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet (2005) 2.68
Cutting edge: Toll-like receptor (TLR)2- and TLR4-mediated pathogen recognition in resistance to airborne infection with Mycobacterium tuberculosis. J Immunol (2002) 2.67
TLR13 recognizes bacterial 23S rRNA devoid of erythromycin resistance-forming modification. Science (2012) 2.66
IL-22 is expressed by Th17 cells in an IL-23-dependent fashion, but not required for the development of autoimmune encephalomyelitis. J Immunol (2007) 2.60
CCR2+Ly-6Chi monocytes are crucial for the effector phase of autoimmunity in the central nervous system. Brain (2009) 2.59
Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection. Hepatology (2009) 2.48
Inhibition of transcription factor NF-kappaB in the central nervous system ameliorates autoimmune encephalomyelitis in mice. Nat Immunol (2006) 2.48
Autologous haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis. Brain (2007) 2.46
Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood (2011) 2.44
Remyelination is extensive in a subset of multiple sclerosis patients. Brain (2006) 2.43
Yersinia V-antigen exploits toll-like receptor 2 and CD14 for interleukin 10-mediated immunosuppression. J Exp Med (2002) 2.41
Rorγt+ innate lymphocytes and γδ T cells initiate psoriasiform plaque formation in mice. J Clin Invest (2012) 2.40
The endoplasmic reticulum-resident heat shock protein Gp96 activates dendritic cells via the Toll-like receptor 2/4 pathway. J Biol Chem (2002) 2.39
Requirement of JNK2 for scavenger receptor A-mediated foam cell formation in atherogenesis. Science (2004) 2.38
Distinct and non-redundant roles of microglia and myeloid subsets in mouse models of Alzheimer's disease. J Neurosci (2011) 2.31
Axonal loss and neuroinflammation caused by peroxisome-deficient oligodendrocytes. Nat Genet (2007) 2.30
APC-derived cytokines and T cell polarization in autoimmune inflammation. J Clin Invest (2007) 2.28
Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain (2002) 2.27
Microglial phenotype: is the commitment reversible? Trends Neurosci (2006) 2.18
IL-1β mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4(+) Th17 cells. J Exp Med (2012) 2.11
Tissue preconditioning may explain concentric lesions in Baló's type of multiple sclerosis. Brain (2005) 2.07
Endosomal translocation of vertebrate DNA activates dendritic cells via TLR9-dependent and -independent pathways. J Immunol (2005) 2.02
Antagonistic antibody prevents toll-like receptor 2-driven lethal shock-like syndromes. J Clin Invest (2004) 1.96
Toll-like receptor 2 participates in mediation of immune response in experimental pneumococcal meningitis. J Immunol (2003) 1.93
Interleukin 18-independent engagement of interleukin 18 receptor-alpha is required for autoimmune inflammation. Nat Immunol (2006) 1.92
Microglia in the CNS: immigrants from another world. Glia (2011) 1.90
Foxp3(+) regulatory T cells promote T helper 17 cell development in vivo through regulation of interleukin-2. Immunity (2011) 1.87
MyD88 plays a unique role in host defense but not arthritis development in Lyme disease. J Immunol (2004) 1.85
Cellular mechanisms of IL-17-induced blood-brain barrier disruption. FASEB J (2009) 1.82
Maternal TLR signaling is required for prenatal asthma protection by the nonpathogenic microbe Acinetobacter lwoffii F78. J Exp Med (2009) 1.79
Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc Natl Acad Sci U S A (2006) 1.79
Neuronal injury in bacterial meningitis: mechanisms and implications for therapy. Trends Neurosci (2002) 1.78
Mechanisms of acute axonal degeneration in the optic nerve in vivo. Proc Natl Acad Sci U S A (2010) 1.70
Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol (2012) 1.70
Cutting edge: myeloid differentiation factor 88 deficiency improves resistance against sepsis caused by polymicrobial infection. J Immunol (2002) 1.70
The major surface protein of Wolbachia endosymbionts in filarial nematodes elicits immune responses through TLR2 and TLR4. J Immunol (2004) 1.68
Audio-visual biofeedback for respiratory-gated radiotherapy: impact of audio instruction and audio-visual biofeedback on respiratory-gated radiotherapy. Int J Radiat Oncol Biol Phys (2006) 1.67
Distinct lesion morphology at 7-T MRI differentiates neuromyelitis optica from multiple sclerosis. Neurology (2012) 1.67
Circulating monocytes engraft in the brain, differentiate into microglia and contribute to the pathology following meningitis in mice. Brain (2006) 1.63
Early MRI changes in a mouse model of multiple sclerosis are predictive of severe inflammatory tissue damage. Brain (2007) 1.63
Frontal white matter microstructure, aggression, and impulsivity in men with schizophrenia: a preliminary study. Biol Psychiatry (2002) 1.62
Neo-lymphoid aggregates in the adult liver can initiate potent cell-mediated immunity. PLoS Biol (2009) 1.60
Containment of aerogenic Mycobacterium tuberculosis infection in mice does not require MyD88 adaptor function for TLR2, -4 and -9. Eur J Immunol (2008) 1.59
Local type I IFN receptor signaling protects against virus spread within the central nervous system. J Immunol (2009) 1.57
Acute effects of intracranial hypertension and ARDS on pulmonary and neuronal damage: a randomized experimental study in pigs. Intensive Care Med (2011) 1.57
Extracellular and intracellular pattern recognition receptors cooperate in the recognition of Helicobacter pylori. Gastroenterology (2009) 1.57
Preferential loss of myelin-associated glycoprotein reflects hypoxia-like white matter damage in stroke and inflammatory brain diseases. J Neuropathol Exp Neurol (2003) 1.55
Microglia inflict delayed brain injury after subarachnoid hemorrhage. Acta Neuropathol (2015) 1.51
Cytokine complex-expanded natural killer cells improve allogeneic lung transplant function via depletion of donor dendritic cells. Am J Respir Crit Care Med (2013) 1.50
Natural killer cell and macrophage cooperation in MyD88-dependent innate responses to Plasmodium falciparum. Proc Natl Acad Sci U S A (2005) 1.50
Plasminogen activator inhibitor-1 from bone marrow-derived cells suppresses neointimal formation after vascular injury in mice. Arterioscler Thromb Vasc Biol (2006) 1.49
Widespread demyelination in the cerebellar cortex in multiple sclerosis. Brain Pathol (2007) 1.49
Structural model of MD-2 and functional role of its basic amino acid clusters involved in cellular lipopolysaccharide recognition. J Biol Chem (2004) 1.48
TLR4/MD-2 monoclonal antibody therapy affords protection in experimental models of septic shock. J Immunol (2007) 1.48
Ablation of the sympathetic nervous system decreases gram-negative and increases gram-positive bacterial dissemination: key roles for tumor necrosis factor/phagocytes and interleukin-4/lymphocytes. J Infect Dis (2005) 1.48
Mammalian target of rapamycin (mTOR) orchestrates the defense program of innate immune cells. Eur J Immunol (2008) 1.46
Toll-like receptor 2 signaling triggers fatal arrhythmias upon myocardial ischemia-reperfusion. Crit Care Med (2010) 1.45
Ectopic expression of neural autoantigen in mouse liver suppresses experimental autoimmune neuroinflammation by inducing antigen-specific Tregs. J Clin Invest (2008) 1.44
Iron and neurodegeneration in the multiple sclerosis brain. Ann Neurol (2013) 1.43
Lymphotoxin β receptor signaling promotes development of autoimmune pancreatitis. Gastroenterology (2012) 1.43
IL-12 initiates tumor rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor NKp46. Nat Immunol (2010) 1.43
Extensive cortical remyelination in patients with chronic multiple sclerosis. Brain Pathol (2007) 1.41
IL-23: one cytokine in control of autoimmunity. Eur J Immunol (2012) 1.40
SIRT1 decreases Lox-1-mediated foam cell formation in atherogenesis. Eur Heart J (2010) 1.40